Generic Drug News and Research

RSS

Generic Drugs are official nonbrand names by which medicines are known. Generic names usually refer to the chemical name of the drug.

Autistic children have a capacity to understand other people through stereotypes

The research shows that autistic children are just as able as others to predict people's behaviour when stereotypes, such as gender and race, are the only available guide.

19 Jun 2007

Lupin announces FDA approval of Trandolapril tablets

Lupin Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted final approval for the Company's Abbreviated New Drug Application (ANDA) for Trandolapril Tablets, 1mg, 2mg and 4mg. Commercial shipments of Trandolapril tablets have commenced.

17 Jun 2007

U.S. DOJ investigation of Bristol-Myers Squibb in Plavix patent settlement resolved

Bristol-Myers Squibb has pleaded guilty to two counts of violating 18 U.S.C. Sec. 1001 in U.S. District Court for the District of Columbia. This guilty plea resolved as to the company the previously disclosed investigation by the Antitrust Division of the U.S. Department of Justice into the proposed settlement of the Plavix patent litigation with Apotex Inc., and Apotex Corp. (Apotex).

16 Jun 2007

Growth in ADHD medication use due to improved ADHD identification in adult and female patients

Attention deficit hyperactivity disorder (ADHD) has been traditionally viewed as a childhood disorder, while ADHD in adults has been underdiagnosed and undertreated.

8 Jun 2007

Directly observed HIV therapy for children is promising

Directly observed antiretroviral therapy is a promising strategy to ensure that HIV-infected children in developing countries take life-saving medications, new research from The Warren Alpert Medical School of Brown University shows.

3 Jun 2007

Ranbaxy successfully challenges Atorvastatin patents in Norway

Ranbaxy Laboratories Limited (RLL) announced that the Norwegian Appeals Court today handed down a favorable decision for Ranbaxy in its case against Pfizer, involving key Norwegian patents on Atorvastatin in Norway.

1 Jun 2007

Mylan wins Omeprazole patent litigation

Mylan Laboratories Inc. has announced that the United States District Court for the Southern District of New York has ruled that Mylan's 10 mg and 20 mg omeprazole delayed-release capsules, which are the generic versions of AstraZeneca LP's Prilosec, do not infringe patents asserted against it by AstraZeneca.

1 Jun 2007

Mylan receives FDA approval for Azithromycin tablets

Mylan Laboratories Inc. ( NYSE:MYL ) today announced that Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Applications (ANDAs) for Azithromycin Tablets, 250 mg and 500 mg.

1 Jun 2007

Lupin receives FDA approval for Ziprasidone Hydrochloride capsules

Lupin Pharmaceuticals has announced that on May 16, 2007 it received tentative approval from the US FDA for its Abbreviated New Drug Application (ANDA) for Ziprasidone Hydrochloride Capsules 20mg, 40mg, 60mg and 80mg.

24 May 2007

Combination of medicines best for blood pressure control

Millions of Americans take medications for hypertension but do not achieve control of their blood pressure.

22 May 2007

Weill Cornell Medical College students help change global health policy

In a move to improve global public health, Weill Cornell Medical College students have helped place a lifesaving heart disease drug onto the World Health Organization's (WHO) list of essential medicines.

22 May 2007

Ranbaxy receives tentative FDA approval for Fexofenadine hydrochloride tablets

Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), has announced that RLL has received tentative approval from the U.S. Food and Drug Administration to manufacture and market the antihistamine Fexofenadine Hydrochloride Tablets, 30 mg, 60 mg, and 180 mg.

18 May 2007

Lupin Pharmaceuticals receives FDA approval for Simvastatin tablets

Lupin Pharmaceuticals, Inc. has announced that it has received final approval from the US FDA for its Abbreviated New Drug Application (ANDA) for Simvastatin Tablets 10mg, 20mg, 40mg and 80mg.

16 May 2007

More power to FDA on drug safety

The Senate overwhelmingly passed significant prescription drug safety reforms to give the Food and Drug Administration more power to deal with unsafe medicines on the market, moving the issue of drug safety to the House, where a strong bill has been introduced but has yet to be considered.

10 May 2007

Review of six large-scale clinical trials of aliskiren

Hypertension is a serious condition affecting millions.Currently there are seven classes of drugs used to reduce blood pressure. Aliskiren (Tekturna , Rasilez) is the first of a new class of orally active antihypertensive drugs that works by inhibiting renin.

10 May 2007

Clinton to the rescue again!

Bill Clinton has done deal with two generic drug companies which will ensure that developing countries will be able to access second line anti-retroviral AIDS drugs at reduced prices.

8 May 2007

Elastic interactions of membrane proteins

Cellular survival relies crucially on the ability to receive and communicate signals from and to the outside world.

4 May 2007

FDA issues "Critical Path Opportunities for Generic Drugs"

The U.S. Food and Drug Administration (FDA) today issued the "Critical Path Opportunities for Generic Drugs" report identifying many of the unanswered scientific questions that impede the development of generic versions of commonly used drugs.

4 May 2007

AIDS Healthcare Foundation praises Thailand for drug stance

AIDS Healthcare Foundation (AHF) has lauded the Government of Thailand for its vow to continue with plans to issue compulsory licenses for the manufacturing and importing of generic versions of lifesaving drugs, including AIDS drugs, despite the fact that the office of United States Trade Representative (USTR), elevated Thailand to its 'Priority Watch' List.

4 May 2007

Senate begins debate on prescription drug user fee act reauthorization bill

The Senate on Monday began debate on a bill (S 1082) that would reauthorize the Prescription Drug User Fee Act, which will expire on Sept. 30, with senators expected to propose a number of amendments to the legislation, the AP/Dallas Morning News reports ( AP/Dallas Morning News , 4/30).

2 May 2007